

Docket No.: GLYO-P03-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Chang et al.

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: September 8, 2003

Examiner: Not Yet Assigned

For: METHOD FOR ENHANCING THE
EFFECTIVENESS OF CANCER
THERAPIES

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail EV324845257US, postage prepaid, in an envelope addressed to: MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below:

September 8, 2003
Date of Signature and of Mail Deposit


Mary Jane DiPalma

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Those patent(s) or publication(s) in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior application no. 10/176,235, filed on June 20, 2002 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GLYO-P03-002.

Date: September 8, 2003

Customer No: 28120
Docketing Specialist
Ropes & Gray LLP
One International Place
Boston, MA 02110
Phone: 617-951-7615
Fax: 617-951-7050

Respectfully Submitted,



David P. Halstead, Ph.D.
Reg. No: 44,735

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
		Application Number	Not Yet Assigned		
		Filing Date	September 8, 2003		
		First Named Inventor	Yan Chang		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
		Attorney Docket Number	GLYO-P03-002		
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,681,923	10-28-1997	Platt	
	AB	US-5,843,442	12-01-1998	Soule et al.	
	AC	US-5,895,784	04-20-1999	Raz et al.	
	AD	US-6,423,314-B2	07-23-2002	Platt	
	AE	US-5,490,991	02-13-1996	Enriquez et al.	
	AF	US-6,500,807	12/2002	Platt et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Inohara, H. et al., "Effects of Natural Complex Carbohydrate (Citrus Pectin) on Muriine Melanoma Cell Properties Related to Galectin-3 Functions," Glycoconjugate Journal 11:527-532 (1994)		
	CB	GBC 590 SafeScience Clinical Data. R&D Focus Drug News, DRUGNL. AN:1186 (2001)		
	CC	Rabinovich G.A. et al., "Galectins and Their Ligands: Amplifiers, Silencers or Tuners of the Inflammatory Response?" Trends in Immunology 23(6):313-320 (2002)		
	CD	Huei-Min Lin et al., "Calectin-3 Mediates Genistein-induced G2/M Arrest and Inhibits Apoptosis," Carcinogenesis 21(11):1941-1945 (2000)		
	CE	Hyeong-Reh Choi Kim et al., "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," Cancer Research 59:4148-4154 (1999)		
	CF	Pratima Nangia-Makker et al., "Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis," American Journal Pathology 156(3):899-909 (2000)		
	CG	Wen-Qin Zhu et al., "Rapid Release of Intracellular Galectin-3 from Breast Carcinoma Cells by Fetuin," Cancer Research 61:1869-1873 (2001)		
	CH	Vladislav V. Glinsky et al., "Effects of Thomsen-Friedenreich Antigen-specific Peptide P-30 on B-Galactoside-mediated Homotypic Aggregation and Adhesion to the Endothelium of MDA-MB-435 Human Breast Carcinoma Cells," Cancer Research 60:2584-2588 (2000)		
	CI	Vladislav V. Glinsky et al., "The Role of Thomsen-Friedenreich Antigen in Adhesion of human Breast and Prostate Cancer Cells to the Endothelium," Cancer Research 61:4851-4857 (2001)		
	CJ	Hyeong-Reh Choi Kim et al., "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," Cancer Research 59:4148-4154 (1999)		
	CK	Hua Chang Gon et al., "The NH2 Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells," Cancer Research 59:6239-6245 (1999)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	GLYO-P03-002

	CL	Pascal O. Berberat et al., "Comparative Analysis of Galectins in Primary Tumors of Tumor Metastasis in Human Pancreatic Cancer," The Journal of Histochemistry & Cytochemistry 49(4):539-549 (2001)	
	CM	Ida Iurisci et al., "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," Clinical Cancer Research 6:1389-1393 (2000)	
	CN	Nachman Mazuret et al., "Phosphorylation of the B-Galactoside-binding Protein Galectin-3 Modulates Binding to its Ligands," The Journal of Biological Chemistry 275(46):36311-36315 (2000)	
	CO	S.E. Baldus et al., "Increased Galectin-3 Expression in Gastric Cancer: Correlations with Histopathological Subtypes, Galactosylated Antigen and Tumor Cell Proliferation," Tumor Biol., 21:258-266 (2000)	
	CP	Matarresse et al., (Abstract) "Galectin-3 Overexpression Protects from Apoptosis by Improving Cell Adhesion Properties," Int. Cancer 85(4):545-554 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--